Clinical trial
Efficacy and Safety of RTH258 Versus Aflibercept - Study 2
NCT02434328 · Alcon Research, Industry · Completed
Key facts
| NCT number | NCT02434328 |
|---|---|
| Title | Efficacy and Safety of RTH258 Versus Aflibercept - Study 2 |
| Official title | A Two-year, Randomized, Double-masked, Multicenter, Two-arm Study Comparing the Efficacy and Safety of RTH258 6 mg Versus Aflibercept in Subjects With Neovascular Age-related Macular Degeneration |
| Acronym | HARRIER |
| Lead sponsor | Alcon Research, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization |
| Intervention type | Drug |
| Interventions | Brolucizumab ophthalmic solution, Aflibercept ophthalmic solution |
| Enrollment | 1,048 |
| Start date | Jul 28, 2015 |
| Primary completion | Apr 5, 2017 |
| Completion | Mar 8, 2018 |
| First posted | May 5, 2015 |
| Last update posted | Jan 16, 2025 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: